Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: corticosteroids

Concerning the Back: Updates in AS & nr-axSpA

  |  

During the 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of the Rheumatic Diseases Symposium, Dr. Atul Deodhar provided an overview on axial spondyloarthritis (axSpA) and non-radiographic axSpA, with helpful insights into the diagnosis and care of patients with these conditions.

Ethics Forum: Mitigation Tips for Health Disparities Among Rural & Indigenous Peoples

Laura Nichols, MD, Lee Graham, MD, & Erdal Diri, MD  |  

A common case scenario in our practice in North Dakota is a woman with rheumatoid arthritis on methotrexate monotherapy. She is a member of the Sisseton Wahpeton Oyate people and lives 90 miles from our rheumatology clinic. She currently has moderate disease activity, indicating the need for additional treatment. She does not have her own…

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

  |  

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

RheumMadness 2023: The Results Are In

David L. Leverenz, MD, MEd  |  

RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…

Mixed Results for Rezpegaldesleukin in Patients with Active SLE

  |  

In a clinical trial, patients with active systemic lupus erythematosus (SLE) did not experience a reduction in disease activity with the addition of rezpegaldesleukin to their standard treatments. However, some patient populations did see improvements in their disease activity compared with the placebo-treated group.

Lost and found

A Look Back at the First Use of Cortisone in Rheumatoid Arthritis

  |  

In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of…

Options for Refractory Gout, ILD & More

  |  

PHILADELPHIA—At the first Plenary Session of ACR Convergence 2022, on Saturday, Nov. 12, speakers shared key research findings on the efficacy and safety of methotrexate as a co-therapy with pegloticase in refractory gout, the effectiveness of rituximab and cyclophosphamide in connective tissue disease associated-interstitial lung disease and the value of remote education for primary care…

Ethics Forum: Has the Patient Asked for More Than Can Be Ethically Allowed?

Richard L. Allman, MD, MS, FACP, FACR  |  

The patient, a 76-year-old woman, had very active polyarticular rheumatoid arthritis (RA), despite triple therapy with conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), low-dose corticosteroids and occasional intra-articular injections—the latter providing only transient symptomatic relief. She had elevated inflammatory markers and a 28-joint Disease Activity Score (DAS-28) score of 7.4.  Because of the severity of her…